Literature DB >> 3992428

Intravenous miconazole therapy for experimental keratomycosis in rabbits.

Y Ishibashi, Y Matsumoto.   

Abstract

Intravenous miconazole (90 mg daily for 3 weeks) reduced the intensity of experimental fungal keratitis due to Candida albicans in a group of 10 rabbits. Clinical scores of affected eyes were statistically significantly lower in the treated group than in a control group of 10 untreated rabbits. All cultures of corneal scrapings were negative on 18th day after inoculation in the treated group, but four cultures were still positive on the 21st day in the control animals. Histopathological examination of eyes from treated and untreated rabbits showed great differences in the severity of inflammatory changes in the two groups.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3992428     DOI: 10.1080/00362178585380091

Source DB:  PubMed          Journal:  Sabouraudia        ISSN: 0036-2174


  5 in total

Review 1.  Overview of medically important antifungal azole derivatives.

Authors:  R A Fromtling
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

2.  Orally administered antifungal therapy for experimental keratomycosis.

Authors:  D M O'Day
Journal:  Trans Am Ophthalmol Soc       Date:  1990

3.  Clinical and experimental mycotic keratitis caused by Aspergillus terreus and the effect of subconjunctival oxiconazole treatment in the animal model.

Authors:  S M Singh; S Sharma; P K Chatterjee
Journal:  Mycopathologia       Date:  1990-12       Impact factor: 2.574

4.  The pathogenicities of Cylindrocarpon tonkinense and Fusarium solani in the rabbit cornea.

Authors:  Y Ishibashi; H E Kaufman; T Matsumoto; S Kagawa
Journal:  Mycopathologia       Date:  1986-06       Impact factor: 2.574

5.  Clinical and experimental mycotic corneal ulcer caused by Aspergillus fumigatus and the effect of oral ketoconazole in the treatment.

Authors:  S M Singh; R Khan; S Sharma; P K Chatterjee
Journal:  Mycopathologia       Date:  1989-06       Impact factor: 2.574

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.